Sun Pharma Advanced Research Company Consolidates R&D Laboratories to Accelerate Pipeline Assets

Sun Pharma Advanced Research Company Ltd (SPARC) has announced a strategic consolidation of its R&D infrastructure and laboratories from multiple sites in Mumbai and Baroda to two sites in Baroda. This move aims to streamline R&D operations, enhance operational efficiencies, and reduce cycle times, thereby accelerating the proof-of-concept of pipeline assets. The consolidation will integrate the R&D operations conducted at Mahakali site in Mumbai and Makarpura site in Baroda into the Company’s Savli and Tandalja sites in Baroda. As part of the overall cost optimization effort, the Company will outsource some of the R&D activities to third party partners. The transition is not expected to impact the prioritization and scale of the current pipeline. The consolidation could result in excess capacity in certain functions, which the Company aims to streamline by the end of FY26. The corporate functions will continue to operate out of Mahakali office in Mumbai.